


Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Level of hospital care according to NYA functional classification



Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Introduction

- > Between 1 % and 3 % of women will have a form of cardiac disease diagnosed before or during pregnancy
- > Cardiac pathology may be:
 - > Congenital or acquired
 - > Functional or structural
 - > Cyanotic or non-cyanotic
 - > Or may include endocardial, myocardial or pericardial defects (Gei, Hankins 2001)
- > Specific hazards for women with cardiac disease in pregnancy include:
 - > The occurrence of pulmonary oedema (main cause of death)
 - > Pulmonary hypertension
 - > Infective endocarditis
 - > Thromboembolism
 - > Fulminating peripartum cardiomyopathy
 - > Aortic dissection, arrhythmias
- > The most frequent causes of cardiac disease in pregnancy are:
 - > Rheumatic heart disease
 - > Congenital heart disease
 - > Arrhythmias
 - > Ischemic heart disease
 - > Heart failure
- > Fetal risks
 - > Congenital heart disease
 - > Intrauterine growth restriction
 - > Prematurity

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

New York Heart Association (NYHA) functional classification

- > Classification of the severity of heart disease can aid in the prediction of maternal and neonatal outcomes and in the counselling of prospective parents (Davies, Herbert 2007a)

Class	Clinical Implications	Objective Assessment
I	Good tolerance of exercise without symptoms (chest pain, angina, dyspnoea, palpitations, fatigue)	No objective evidence of cardiovascular disease
II	Symptomatic with moderate exercise	Objective evidence of minimal cardiovascular disease
III	Symptomatic with light exercise or ordinary activities	Objective evidence of moderately severe cardiovascular disease
IV	Symptomatic at rest	Objective evidence of severe cardiovascular disease

Adapted from American Heart Association. In: Dobbenga-Rhodes YA, Privé AM. Assessment and evaluation of the woman with cardiac disease during pregnancy. J Perinat Neonat Nurs 2006; 20: 295-302.

Preconception care

- > Assessment of the woman's general physical condition, medications and cardiac function
- > Optimise management of hypertension / arrhythmias
- > Assess lifestyle risk factors e.g. smoking and education to optimise exercise tolerance
- > Ideally, discussions should occur between the woman, her family and a cardiologist, physician, obstetrician and / or anaesthetist familiar with the management of cardiac diseases in pregnancy to agree and decide on the best timing for pregnancy
- > Points to be discussed include:
 - > The natural history of the woman's disease, including the possibility of a successful pregnancy through medical treatment and optimising the woman's cardiac function
 - > Present clinical staging of cardiac disease as per New York Heart Association functional classification
 - > Optimising the woman's clinical condition by changes in medications or surgical procedures before conception
 - > Expected outcomes including chance of spontaneous miscarriage, live birth, death, proposed care plan of the pregnancy and implications of admissions, antenatal care, anaesthesia, medications and peripartum management
 - > The risk of transmitting the cardiac condition or syndrome to offspring (Alfredo et al. 2001)

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Antenatal management

- > Routine booking visit around 10 to 12 weeks
- > Early ultrasound to establish estimated date of confinement (EDC)
- > These women should be managed by a multi disciplinary team, which might include an obstetrician, cardiologist or obstetric physician, anaesthetist and intensivist. These clinicians should all be familiar with the management of cardiac problems in pregnancy
- > The woman should be involved in a discussion about the management of the pregnancy. This should include:
 - > Decision about the most appropriate facility to deliver the woman and criteria for changing the place of birth
 - > Antenatal visits in high risk medical clinic every 2 weeks if required because of severity of disease
 - > Regular review of functional cardiac status at each visit
 - > Echo cardiograms with timely follow up by Obstetrician and Cardiologist
 - > Avoid anaemia – iron supplementation, prenatal vitamins and dietary counselling and regular haemoglobin checks
 - > Ongoing discussion regarding work schedules and levels of activity
 - > Arrange anaesthetic review before 28 weeks

Clinical assessment

History

- > Maternal age, gestational age, parity status, NYHA functional classification, comorbid conditions, previous cardiac events / surgery / interventions, cardiac lesions, cyanosis (oxygen saturation < 90 %), medications, use of cigarettes and / or alcohol

Investigations

- > 12-lead electrocardiogram (ECG)
- > Echocardiographic assessment to determine:
 - > Systemic (left) and venous (right) ventricular systolic function,
 - > Doppler quantification of inflow or outflow obstruction
 - > Doppler quantification of valvular function
 - > Right heart pressures and systolic if measurable (Siu et al. 2001)

Fetal wellbeing

- > Women with cyanotic heart disease, NYHA III or IV, left heart obstruction, smokers, multiple gestation and anticoagulation are at high risk of having a fetus with growth restriction. These women should be offered regular ultrasound assessments of fetal well being (growth, umbilical artery Doppler, AFI) and cardiotocography in the third trimester

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Fetal risks

- > Fetal cardiac assessment is necessary because there is a 2 to 16 % risk of congenital heart disease in the fetus in pregnant woman with congenital heart disease. The incidence of congenital heart disease in the offspring is more common in the fetus when the mother, rather than the father, is affected, particularly if the mother has a condition such as bicuspid aortic valve, which is more common in the male
- > Early diagnosis of congenital heart defect in the fetus (before 24 weeks of gestation) allows the possibility of termination of the pregnancy (TOP)
- > Affected fetuses benefit from delivery in a tertiary care centre with Paediatric Cardiac Support
- > The two main determinants of fetal prognosis are maternal functional class and the degree of maternal cyanosis. When the mother is in functional class III to IV, or has a high risk disease such as severe aortic stenosis or Eisenmenger syndrome or is cyanosed, monitoring of fetal growth is very important
- > Neonatal survival is low before 28 weeks (< 75 %) and the risk of cerebral palsy in the surviving neonates is high (10–14 %). Therefore, when cardiac function is reduced to critical levels, surgery or percutaneous procedures to improve maternal cardiac function should be undertaken, if feasible, in order to postpone delivery as long as possible
- > The choice between corrective procedures and delivery may be difficult between 28 and 32 weeks, and decisions must be individualized. If the fetus is going to be delivered at < 34 weeks, lung maturation must be induced by betamethasone administration to the mother

Level of hospital care (see Table 64.1)

- > Echocardiographic assessment results and the ongoing NYHA functional classification will determine if the level of hospital care required is:
 - > Hospital of choice care (must be at least Level 4)
 - > Tertiary centre care (Level 5 or 6)
 - > Tertiary centre with onsite specialist adult cardiac service care and adult intensive care (available at some Level 5 or 6 hospitals)
- > It may be possible for some women to have some antenatal visits with a geographically closer unit ("shared care") if delivery at a higher level unit is required. This should be negotiated on a case by case basis
- > Women with NYHA functional class I will usually require care in a tertiary centre (Level 4, 5 or 6)
- > Women with NYHA functional class II, III, IV may be referred to a hospital with onsite specialist adult cardiac service care and adult intensive care (Level 5 or 6), particularly if there is a history of:
 - > Severe cardiac condition (see specific cardiac conditions)
 - > Valve replacement or other cardiac surgery
 - > Any particular risk of endocarditis
- > Referral to a hospital with specialist adult cardiac service (Level 5 or 6) may be required if condition worsens

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Cardiac condition stable:

- > Aim for vaginal birth at term (see individual cardiac diagnoses for specific contra indications for vaginal delivery)
- > Consider caesarean section only for obstetric indications
- > Inform the woman that decisions about her management may change at short notice
- > Maintain ongoing communication within the high risk medical team
- > Further investigations may be indicated, e.g. echo, chest X ray etc

Specific conditions

Benign arrhythmias

- > Includes sinus tachycardia, premature atrial and ventricular contractions, paroxysmal supraventricular tachycardia (SVT), atrial fibrillation, atrial flutter
- > The majority of women with arrhythmias during pregnancy have a benign increased rate of atrial or ventricular premature beats (Davies, Herbert 2007e). Both ectopic beats and sustained arrhythmias become more frequent during pregnancy. They may even develop for the first time. In general they are treated in the same way as non pregnant patients, but as conservatively as possible. Definitive treatment is reserved for the post partum period if it is safe to do so. Women who are worried about ectopic beats can usually be reassured unless the frequency increases on exercise
- > Haemodynamically stable women do not usually require treatment
- > Advise woman to avoid precipitating factors such as caffeine, alcohol, tobacco, fatigue and anxiety

Other arrhythmias

- > Women with more ominous atrial arrhythmias (supraventricular tachycardia, atrial fibrillation and flutter) should be managed in collaboration with a cardiologist, usually using the same agents that would be chosen in the non pregnant woman, including electrical cardioversion when necessary (Davies, Herbert 2007e)
- > All commonly used anti-arrhythmic drugs cross the placenta. The pharmacokinetics of drugs are altered in pregnancy and require close clinical monitoring to ensure maximum efficacy and avoid toxicity
- > Supraventricular tachycardias are corrected by vagal stimulation or, failing that, intravenous adenosine. If adenosine is unsuccessful at restoring sinus rhythm consider using β -blockers or verapamil. Electrical cardioversion is not contraindicated and should be used for any sustained tachycardia causing haemodynamic instability and therefore threatening fetal wellbeing. Beta blocking drugs with beta-1 selectivity are the first choice for prophylaxis. Verapamil is constipating but may be used if there is a contraindication to β -blocker use (such as asthma)

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

- > Both β -blockers and the dihydropyridone calcium antagonists can cause fetal bradycardia. If the arrhythmia is uncontrolled and severely compromising the health of the mother and fetus, radio frequency ablation for atrio ventricular (AV) nodal re-entry or certain atrio ventricular re-entry tachycardias can, if necessary, be performed during pregnancy with suitable lead shielding and maximal use of echo rather than X-ray fluoroscopy
- > Class I agents such as Flecainide may be considered if the maternal left ventricle is normal. Information on its use in pregnancy is limited. Of the Class III agents, Sotalol is much more preferable to amiodarone and has similar risks to β -blockers with the increased risk of torsades de pointes due to QT prolongation. Amiodarone should be avoided unless the maternal arrhythmia is life-threatening to the mother or fetus, other agents have failed and the arrhythmia is not manageable with radiofrequency (RF) ablation. Long term use of Amiodarone can cause neonatal hypothyroidism (9 % of newborns), hyperthyroidism, and goitre
- > Potentially life threatening ventricular tachyarrhythmias are much less common and should be terminated by electrical cardioversion if causing maternal haemodynamic compromise. Management requires the opinion of a cardiologist and should be managed as in the non-pregnant woman. This includes the use of antiarrhythmic medication in the short- to long-term and / or the likely insertion of an automatic internal cardiac defibrillator (ICD)

Pacemakers and automatic internal cardiac defibrillators (ICD)

- > The presence of a pacemaker or an ICD does not itself contraindicate pregnancy. The presence of any underlying structural heart disease determines the risk of pregnancy
- > Pregnancy in patients with an ICD does not cause increased ICD-related complications or adverse events in the mother or fetus; neither does it increase the number of ICD discharges
- > A pacemaker for the alleviation of symptomatic bradycardia, or ICD can be implanted at any stage of pregnancy using X-ray fluoroscopy with suitable lead shielding and echo guidance
- > Any woman with an ICD should be advised to carry identification information about the ICD type, date implanted, and location of implantation in her South Australian pregnancy record. A plan for deactivation in case of an emergency should be documented in her South Australian pregnancy record.
- > The presence of a pacemaker or ICD should not alter the mode of delivery. This is determined by obstetric indications
- > If Caesarean section is required, the ICD should be temporarily inactivated (preferably by reprogramming or in an emergency by application of a magnet over the generator) until the procedure is finished. While inactivated, the patient should have continuous ECG monitoring and external defibrillation available at all times

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Rheumatic heart disease and mitral stenosis

- > The incidence of rheumatic heart disease is decreasing in developed countries. Mitral stenosis is the most common sequelae
- > In women with rheumatic heart disease, the mitral valve is most commonly affected. Mitral stenosis occurs in 90 % of cases, mitral regurgitation in 7 %, aortic regurgitation 2.5 % and aortic stenosis in 1 % of cases of rheumatic heart disease (Davies, Herbert 2007c)

Mitral stenosis

- > Women with mild (NYHA class I) mitral stenosis may be asymptomatic until pregnancy – the increase in left atrial pressure may lead to subsequent symptoms of dyspnoea, and eventually tachypnoea, orthopnoea, and paroxysmal nocturnal dyspnoea
- > Manage according to symptoms and with the guidance of echocardiography, which is the key to the assessment of valvular severity. Mitral stenosis is considered severe and associated with significant increased maternal and fetal risk when the mitral valve area is estimated to be $< 1.5 \text{ cm}^2$, the functional capacity is NYHA III or IV or the right heart pressures rise significantly (estimated PA systolic pressure $> 50 \text{ mmHg}$ or $> 75 \%$ of the systemic pressure)

Medical treatment

- > Limitation of exercise, fluid and salt restriction should be used when the functional class is NYHA II or more
- > In cases of poor functional tolerance, consider oral β -adrenergic blockers (decreases maternal tachycardia), and judicious use of diuretics, avoiding vigorous volume depletion to protect against uteroplacental hypoperfusion (caution in women with severe mitral stenosis – may need concurrent use of invasive haemodynamic monitoring) (Davies, Herbert 2007c)
- > Aggressively cardiovert new onset atrial fibrillation back to sinus rhythm with β -blockers, verapamil and / or direct current (DC) cardioversion (see above)
- > Consider digoxin to control the ventricular response to chronic atrial fibrillation.
- > See anticoagulation prophylaxis for treatment recommendations

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Intervention

- > Women who fail medical treatment during pregnancy with repeated episodes or persistent heart failure should be considered for percutaneous mitral valvotomy if suitable anatomy is present. After successful mitral valvotomy, pregnancy can often continue successfully to term
- > Surgical replacement of the mitral valve is used as a last resort with high fetal risk of peri-operative death. If possible, this should be delayed until the fetus is viable and can be delivered before the surgical intervention

Intrapartum

- > The mode of delivery is determined by obstetric indications only.
- > Care in tertiary centre for NYHA functional class I, II. These patients can be managed in the delivery suite without invasive monitoring. ECG monitoring to monitor maternal heart rate would be preferable.
- > NYHA functional class III, IV: Refer to hospital with specialist adult cardiac service and invasive monitoring in labour. These patients should be managed in an intensive care setting with invasive monitoring, avoiding haemodynamic stress and having careful control of heart rate. Tachycardia can be prevented with intravenous esmolol as necessary
- > Excellent pain control is important and choices should be planned in advance in consultation with the anaesthetist
- > Close monitoring for the first 48 hours after birth

Mitral regurgitation

- > Mitral valve prolapse is the most common cause of mitral regurgitation in women who are pregnant
- > May also be associated with mitral stenosis if the aetiology is of rheumatic fever
- > Pregnancy is generally well tolerated (It is theorised that mitral regurgitation may improve in pregnancy due to the physiologic reduction in systemic vascular resistance)

Medications

- > Pharmacological treatment is not often needed. Diuretics and digoxin can be used for pulmonary congestion. Vasodilator therapy with hydralazine should be used with caution only in those with associated hypertension. ACE inhibitors are considered unsafe for the fetus and are therefore contradicted
- > Previously asymptomatic women may worsen immediately after delivery because of sudden increases in systemic vascular resistance
- > Increased risk of left atrial enlargement and subsequent atrial fibrillation

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Aortic stenosis

- > The most common cause is congenital aortic valve disease (e.g. Bicuspid aortic valve). There is an association with bicuspid aortic valve and aortic root dilatation and co-arctation
- > May also be associated with mitral stenosis if the aetiology is rheumatic fever
- > Maternal mortality associated with severe aortic stenosis is 17 % with a fetal mortality of 32 % (Davies, Herbert 2007c)
- > Echocardiography is essential in determining the severity of the stenosis. In pregnancy an aortic valve area $< 1.0 \text{ cm}^2$ ($0.6 \text{ cm}^2 / \text{m}^2 \text{ BSA}$) is associated with a significant increased maternal and foetal risk
- > Decisions regarding anaesthesia and mode of delivery must be individualised on the basis of obstetric indications, severity of maternal symptoms and aortic valve area
- > In severe or symptomatic aortic stenosis, the intrapartum management should be carried out in a hospital with adult cardiac services and an adult intensive care. Invasive monitoring, especially intra-arterial pressure monitoring is of utmost importance. Avoidance of hypotension and hypovolaemia is essential to avoid haemodynamic collapse

Aortic regurgitation

- > May also be associated with mitral stenosis
- > Clinical course is determined more by the extent of their mitral valve disease than by their aortic regurgitation
- > When aortic regurgitation is the predominant lesion, pregnancy is usually well tolerated and may improve in pregnancy due to the decrease in systemic vascular resistance
- > Also, the physiologic tachycardia of pregnancy may reduce regurgitant flow as diastolic filling times are shortened
- > Murmurs normally associated with both aortic and mitral regurgitation may be reduced in pregnancy
- > Women with severe aortic regurgitation and symptoms of left-sided heart failure should decrease their physical activity and bed rest may be required.
- > Reduce sodium intake $< 2 \text{ g}$ per day
- > Consider diuresis or vasodilators (e.g. hydralazine or nifedipine) and inotropic therapy in difficult cases
- > Despite aggressive medical therapy, some women will require aortic valve replacement in pregnancy. Case reports suggest that pulsatile perfusion at bypass may help preserve placental haemodynamic function (Davies, Herbert 2007c)

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Congenital heart disease

- > May be organised into acyanotic and cyanotic types
- > Acyanotic congenital heart lesions include:
 - > Atrial / ventricular septal defects,
 - > Patent ductus arteriosus, aortic coarctation,
 - > Marfan syndrome,
 - > Aortic / pulmonary stenosis
- > Cyanotic congenital heart lesions include:
 - > Cyanotic congenital heart disease,
 - > Tetralogy of Fallot,
 - > Post Fontan operation
- > Usually require referral to a tertiary centre with specialist adult cardiac service care
- > Fetal echocardiogram at 20 weeks of gestation
 - > If on warfarin, look for echogenic foci in the heels and coccyx, profile to assess nasal bridge
 - > Identified cardiac fetal anomaly carries a 4-5 % risk of associated chromosomal abnormality – recommend amniocentesis with antibiotic prophylaxis as above
- > Most women present as NYHA class I or II lesions and remain largely asymptomatic
- > The risk of a cardiac event in pregnancy is increased for women with:
 - > A prior cardiac event or arrhythmia
 - > NYHA functional class > II
 - > Cyanosis
 - > Left heart obstruction
 - > Systemic ventricular dysfunction

Coarctation of the aorta

- > Coarctation of the aorta should be repaired before pregnancy. It is rare during pregnancy (9 % of all congenital defects). The management of hypertension is difficult in the unoperated pregnant woman. Fetal growth is usually normal and in contrast to essential hypertension, there is not an increased incidence of preeclampsia. Over enthusiastic treatment may cause hypotension in the distal segment. This may result in abortion or fetal death even though pressure in the proximal segment continues to rise on effort
- > Rupture of the aorta is the most common reported cause of death, and rupture of an aneurysm of the circle of Willis has also been reported during pregnancy. The increase in blood volume and cardiac output increases the risk of aortic dissection or rupture during pregnancy and a beta blocker should be prescribed
- > Restriction of physical activity is the only way of minimising potentially dangerous surges in blood pressure
- > Surgical correction is only very rarely indicated during pregnancy if systolic hypertension is uncontrolled or heart failure is present
- > Balloon angioplasty is contraindicated because of the risk of dissection or rupture. Whether this risk is avoidable with stenting is not known

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Marfan syndrome

- > Rare - incidence is 5 in 100,000
- > Mortality rate is high 50 %
- > Women with a documented aortic root diameter of < 40 mm without an abnormal aortic valve have a mortality rate of < 5 %
- > Risk of aortic dissection during pregnancy or shortly thereafter is approximately 17 %
- > Aortic or mitral regurgitation is also seen in 60 % of women with Marfan syndrome and may complicate pregnancy
- > Regular echocardiography before, during and after pregnancy
- > Genetic testing through chorionic villus biopsy, amniocentesis cell culture or postnatal testing
- > B-blockers are strongly recommended before and during pregnancy to decrease the risk of aortic dilatation
- > Pregnancies complicated by Marfan syndrome are not associated with poor perinatal outcomes, though some suggest there is an increased risk of incompetent cervix
- > Physical, echocardiographic, and ophthalmologic examination of newborns
- > Counsel woman regarding the risk of autosomal dominant inheritance and need for follow-up for their offspring (Davies, Herbert 2007b)

Intraatrial repair for transposition of great arteries (TGA)

- > Angiotensin-converting enzyme (ACE) inhibitors should be stopped before pregnancy or as soon as possible. Frequent review is recommended

Congenitally corrected transposition of the great arteries

- > Women without significant other cardiac defects usually do well, but problems can develop through failure of the systemic right ventricle with increasing regurgitation through its tricuspid atrioventricular valve. Supraventricular arrhythmias, embolism, and atrioventricular block are other potential complications

Fontan procedure

- > Careful patient selection is important. The successful Fontan Procedure with a small right atrium or total cavopulmonary connection (TCPC) in functional class I or II can probably complete pregnancy with a normal live birth. Fontan patients with a large right atrium and some venous congestion have to be monitored very carefully. They need anticoagulant treatment and conversion to total cavopulmonary connection before pregnancy is considered

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Prosthetic heart valves

- > The majority of women with bioprosthetic valves do not require anticoagulation during pregnancy (Davies, Herbert 2007e).
- > Women with mechanical valves require anticoagulation prophylaxis and should receive a detailed discussion of the advantages and disadvantages of the three anticoagulant options (warfarin, unfractionated heparin and low molecular weight heparin) (see anticoagulation prophylaxis below)
- > Despite valve replacement there remains a mild functional stenosis across these valves due to the prosthesis itself
- > Women with valve replacements are at high risk of bacterial endocarditis
- > Perform blood cultures if any signs of bacterial endocarditis
- > Observe for signs of cardiac failure e.g. dyspnoea (respirations > 24 per minute), tachycardia (> 130 beats per minute), fatigue, oedema, hypoxia / cyanosis

Warfarin

- > Warfarin crosses the placenta, is teratogenic and may cause haemorrhage in the fetus
- > The teratogenic effects appear to result from inhibition of vitamin K and / or arylsulphatase E activity during skeletal development
- > The fetal warfarin syndrome comprises nasal hypoplasia, short fingers with hypoplastic nails, low birth weight, stippling of epiphyses on X-ray and intellectual disability
- > Recent estimates indicate the risk of fetal warfarin syndrome in babies of women who require warfarin throughout pregnancy is around 5 %
- > The period of greatest embryonic susceptibility is between 6 and 9 weeks of gestation. It is recommended that, wherever possible, the drug is avoided throughout the first trimester (Liebelt, Hotham 2002)

Ischaemic heart disease

- > Includes acute myocardial infarction (MI), unstable angina, stable angina
- > Requires care in a tertiary centre or care in a tertiary centre with specialist adult cardiac service care depending on echocardiograph findings and symptoms according to NYHA functional classification
- > Rare in pregnancy - ischaemic heart disease occurs on average in 1 in 10,000 deliveries
- > Myocardial infarction (MI) in pregnancy occurs on average in 7.5 in 100,000 deliveries with mortality highest in the third trimester in women under 35 years of age (Davies, Herbert 2007d)

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

- > CEMCH 2003-2005 noted an increase in maternal deaths from ischaemic heart disease. The following risk factors were identified:
 - > Obesity
 - > Older age
 - > Higher parity
 - > Smoking
 - > Diabetes
 - > Pre existing hypertension
 - > Family history

Myocardial infarction management

- > Similar to management of the non-pregnant woman with MI and includes:
 - > Oxygen, nitrates, morphine, and most antiarrhythmics, calcium channel blockers, β -blockers, heparin, low-dose aspirin, and invasive hemodynamic monitoring if necessary
 - > Case reports using percutaneous interventions and systemic and local thrombolytic therapy have also been successful (Davies, Herbert 2007d)
- > MI is not an indication for immediate delivery (mortality is higher in women who deliver within 2 weeks of MI)
- > Caesarean section only for obstetrical indications (does not protect women from the dramatic changes in stroke volume and cardiac output associated with the immediate postpartum period)
- > Electrocardiographic monitoring in labour

Heart failure and cardiomyopathy

- > Includes left sided, right heart failure and biventricular heart failure
- > Common causes for heart failure in the puerperium include iatrogenic fluid therapy overload, pre-eclampsia, thyrotoxicosis, peri-partum cardiomyopathy, anaemia or previously undiagnosed rheumatic or congenital heart disease (Davies, Herbert 2007d)

Hypertrophic cardiomyopathy

Clinical assessment

- > Echocardiography
- > electrocardiography (ECG), including ambulatory ECG
- > Exercise testing

Treatment

- > Genetic counselling
- > β -blockers
- > Diuretics
- > Anticoagulation in the presence of atrial fibrillation
- > Amiodarone or implantation of an internal cardiac defibrillator for documented ventricular arrhythmias
- > Dilated cardiomyopathy reversion
- > Normal vaginal birth

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Peripartum or dilated cardiomyopathy

- > Several etiological factors but no specific cause
- > Includes women with unrecognised pre-existing dilated cardiomyopathy and women with acute viral myocarditis during pregnancy
- > Counsel women to avoid pregnancy / consider termination of pregnancy

Clinical assessment

- > Echocardiography

Diagnosis criteria

- > Development of cardiac failure in the last month of pregnancy or within five months postpartum
- > Lack of another cause for the woman's cardiac failure
- > Lack of cardiac disease preceding the month before delivery

Risk factors

- > Older, multiparous women and women with preeclampsia or twins

Symptoms

- > Shortness of breath, lung field crackles, oedema within the first 3 months postpartum

Investigations

- > complete blood count, electrolytes and renal function, electrocardiogram, chest X-ray, arterial blood gases, and an echocardiogram

Treatment

- > Reduce preload and afterload and maximise ventricular contractility
- > Hospitalisation to medically stabilise decompensated heart failure
- > Reduce salt intake < 2 g per day
- > Fluid restriction 1.5 – 2L per day

Medical treatment

- > Diuresis with furosemide
- > In the prepartum period, reduce afterload by using hydralazine and nitrates
- > β -blockers may improve left ventricular systolic function and should be used if not contraindicated once the heart failure is in a compensated state
- > Angiotensin-converting enzyme inhibitors may be safely used to reduce afterload in the postpartum period
- > Digoxin may improve the symptoms of heart failure
- > Avoid or treat severe anaemia to prevent decompensated heart failure
- > Prophylactic anticoagulation while dilation of the heart persists (see anticoagulation prophylaxis)
- > Counsel regarding recurrence risk in future pregnancies. If the woman recovers fully and has normal ventricular function, future pregnancies may be considered

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Heart transplant recipients

- > After heart transplant, approximately 90 % of otherwise healthy young female recipients survive the first year and almost two-thirds will survive the next ten years with an excellent quality of life. These women may desire pregnancy and children (Subramaniam, Robson 2008)
- > These women require high risk care by both transplant physicians and obstetric specialists in a tertiary centre with onsite specialist adult cardiac service care and adult intensive care
- > Pregnancy risks for heart transplant recipients include:
 - > Rejection
 - > Hypertension, pre-eclampsia
 - > Psychological stress
 - > Fetal growth restriction (20 %)
 - > Pre-term birth (up to 50 %)

Preconception counselling

- > Ideally, preconception counselling should be introduced at the pre-transplant stage and continue throughout the post-transplant process
- > Individual factors such as
 - > History of rejection in the first year
 - > Advanced maternal age
 - > Comorbidities (see below)
 - > Medical non-compliance should be considered when counselling women for or against pregnancy
- > Comorbidities that may influence pregnancy outcome include
 - > Risk of recurrent disease
 - > Chronic allograft dysfunction
 - > Cardiovascular or pulmonary disease
 - > Diabetes mellitus
 - > Hypertension
 - > Inherited diseases-maternal or paternal (genetic versus chromosomal)
 - > Hepatitis B, hepatitis C, cytomegalovirus
 - > Obesity
- > Include the woman and her partner in counselling
- > Where possible, vaccinate pre-transplant or pre-pregnancy for influenza, hepatitis B, tetanus, pneumococcus
- > Discuss possible consequences of preterm birth, intrauterine growth restriction with both parents

Timing of pregnancy

- > Before conception ensure:
 - > No rejection in the past year
 - > Adequate and stable graft function
 - > Try to defer pregnancy for at least one year after transplantation
 - > No acute infections that might impact the fetus
 - > Maintenance immunosuppression is at stable doses

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Antenatal care

- > Graft dysfunction during pregnancy warrants appropriate investigation (by biopsy if necessary)
- > Immunosuppression must be maintained during pregnancy to avoid rejection
- > Future studies need to address optimal selection and dosing of these agents
- > Hyperemesis gravidarum may lead to decreased absorption or inadequate immunosuppression
- > Caesarean section indicated only for obstetric reasons

Treatment goals:

- > Ensure that patients maintain graft function using appropriate immunosuppressive dosing during gestation and immediately after delivery
- > Optimise maternal health including graft function
- > Maintain a normal metabolic environment
- > Minimise complications associated with preterm birth
- > Detect and manage hypertensive complications especially preeclampsia
- > Ensure adequate fetal growth

Antibiotic prophylaxis

- > Generally, routine antibiotic prophylaxis is not recommended for women with valvular heart disease undergoing uncomplicated vaginal birth or caesarean section unless infection is suspected (AHA 2007)
- > Intrapartum antibiotic prophylaxis is recommended for vaginal birth complicated by amnionitis (suspected or proven) or prelabour rupture of membranes, and other suspected infections where one of the following cardiac conditions is present:
 - > Prosthetic heart valves
 - > Complex congenital heart disease
 - > Past history of endocarditis
 - > Surgically constructed systemic-pulmonary shunts, or conduits

Recommended intrapartum antibiotic treatment

- > Gentamicin 2 mg / kg IV as a single intrapartum dose given at the commencement of labour and
- > Ampicillin [or amoxycillin] 2 g IV as a stat dose as close as practical to the time of birth

Allergy to penicillin

- > Gentamicin 2 mg / kg IV as a single intrapartum dose given at the commencement of labour and
- > Vancomycin 1 g IV, administered slowly (over at least one hour) and repeat after 8 hours if birth has not occurred

(for further information, refer to the PPG 'Peri partum prophylactic antibiotics')

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Anticoagulation prophylaxis

- > Anticoagulation is indicated for women who have mechanical heart valves, atrial fibrillation or atrial flutter in the presence of structural heart disease, past documented cardiac embolic events, a past history of multiple pulmonary emboli, cyanotic congenital heart defects and Fontan circulation
- > Women with mechanical heart valves are at very high risk of thromboembolism in pregnancy and require continued anticoagulation
- > There are no definitive recommendations about optimal antithrombotic treatments for women with mechanical heart valves in pregnancy
- > Substantial concern remains about the fetal safety of warfarin, the efficacy of subcutaneous unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in preventing thromboembolic complications, and the risk of maternal bleeding with the various regimens (Bates et al. 2004)

A clinically appropriate anticoagulation regimen would be:

- > Warfarin should be avoided between 6 weeks and 12 weeks of gestation (to avoid embryopathy) and close to term (to avoid delivery of an anticoagulated fetus). The association of neuro-developmental problems with mid pregnancy use of warfarin should also be considered (Bates et al. 2004)
 - > Use of one of the following three regimens after explaining the associated risks with the woman:
1. Either LMWH or UFH between 6 weeks and 12 weeks and close to term only. Use vitamin K antagonists e.g. warfarin at other times (despite fetal risks)
 - > If warfarin is used, adjust dose to attain a target INR of 3.0 (a lower therapeutic range of 2.0 to 3.0 can be used in women with mechanical bileaflet aortic valves)
 2. Dose-adjusted subcutaneous UFH throughout pregnancy
 - > Initiate subcutaneous UFH in high doses (start at 17,500-20,000 units every 12 hours) and adjust to prolong a 6 hour post injection APTT into the therapeutic range (at least twice control) or to attain an anti-Xa heparin level of 0.35 to 0.70 U / mL
 3. Dose-adjusted LMWH throughout pregnancy
 - > Administer twice a day in dose to achieve anti-Xa levels of 1.0 to 1.2 U / mL 4 to 6 hours after subcutaneous injection or according to weight.
 - > Aspirin 100 to 150 mg / day may offer additional protection against thromboembolism

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Cardiac conditions associated with high maternal and / or fetal risk during pregnancy

(See Table 64.1)

- > Primary pulmonary hypertension
- > Eisenmenger syndrome
- > Uncorrected coarctation of the aorta
- > Severe atrial stenosis (AS) (valve area < 1 cm²) with or without symptoms
- > Atrial regurgitation (AR) with NYHA functional class III-IV symptoms
- > Mitral stenosis (MS) with NYHA functional class II-IV symptoms and / or valve area < 1.5 cm²
- > Mitral regurgitation (MR) with NYHA functional class III-IV symptoms
- > Aortic and / or mitral valve disease resulting in severe pulmonary hypertension (pulmonary pressure > 75 % of systemic pressures)
- > Aortic and / or mitral valve disease with severe LV dysfunction (EF < 0.40)
- > Mechanical prosthetic valve requiring anticoagulation
- > Marfan syndrome with aortic complications with or without AR
- > History of peripartum cardiomyopathy with persistent left ventricular dysfunction and / or NYHA functional class IV

Management in labour

- > Ensure that adult resuscitation equipment is available including the ability to perform a peri mortem Caesarean Section within 5 minutes of Cardiac Arrest

Management team includes:

- > Obstetrician
- > Midwife
- > Cardiologist / physician
- > Anaesthetist
- > Intensive care specialist
- > Other allied health professionals as required

Thromboembolism prophylaxis

- > Follow link to [regional anaesthesia / analgesia considerations](#) after antenatal administration of intravenous unfractionated heparin or subcutaneous low molecular weight heparin
- > Use anti-embolic stockings

Intrapartum antibiotic prophylaxis

- > Follow link to [antibiotic prophylaxis in cardiac disease](#)

Preterm labour

- > Notify cardiologist / physician if any cardiac advice is required quickly

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Term Labour

- > Most women with cardiac disease should be encouraged to labour spontaneously
- > Syntocinon® infusion for induction or augmentation of labour or prostaglandin E₂ may be used if indicated
- > In women with risk of fluid overload use low volume Syntocinon® infusion (Follow link to Syntocinon® regimen)
- > In fixed cardiac output disorders / aortic aneurysm women may be offered elective caesarean section
- > Ensure intravenous access
- > Maintain continuous midwifery presence and care

Pain management and anaesthesia

- > Nitrous oxide and other pain relief should be provided only after consultation with the anaesthetist
- > An epidural block and assisted vaginal birth may be advised after discussion between the woman, anaesthetist, obstetrician and others
- > Epidural anaesthesia may be hazardous in women with:
 - > A fixed cardiac output
 - > Aortic stenosis
 - > Mitral stenosis
 - > Hypertrophic cardiomyopathy
 - > Fontan circulation
- > Consider combined spinal-epidural anaesthesia (decreases the preload and afterload with a positive effect on most cardiac lesions) (Gei, Hankins 2001)
- > Regional anaesthesia (epidural or spinal) is contraindicated during anticoagulation treatment (risk of spinal haematoma)

Fluid management

- > Closely monitor fluid management in labour and maintain accurate fluid balance chart (increased risk of pulmonary oedema)

Oxygen treatment

- > Oxygen saturation should be continuously monitored with pulse oximetry. Regulate oxygen flow (via mask or nasal specs) to maintain oxygen saturations > 95 %

Signs of cardiac failure:

- > Observe for signs of cardiac failure e.g. dyspnoea (respirations > 24 per minute), tachycardia (> 130 beats per minute [bpm]), fatigue, oedema, cyanosis
- > Position woman in a supported upright sitting position

Continuous electrocardiographic (ECG) monitoring

- > Required in moderate to high risk women
- > Maternal cardiac monitoring should occur throughout labour and after birth for 24 hours, according to the severity of maternal condition
- > High risk women may require invasive cardiac monitoring in labour

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Infection risks

- > Limit vaginal examinations to reduce risk of infection and possible subacute bacterial endocarditis
- > Bacterial endocarditis is a very rare, but serious risk in women with valvular abnormalities and valve replacements. Particular attention should be paid to preventing infection e.g. regular changing of intravenous lines in addition to bacterial endocarditis prophylaxis
- > Report a pulse rate of > 130 bpm and respiratory rate of > 24 respirations per minute (rpm) to senior responsible clinician (physician or cardiologist)

Electronic fetal monitoring

- > Continuous electronic fetal monitoring during labour

Observations

- > Take and record the following observations every fifteen minutes:
 - > Pulse
 - > Respiration
- > Take and record the following observations every hour:
 - > Intake and output
 - > Oedema
 - > Colour
 - > Blood pressure

High risk cardiac management in labour

- > Women with severe or barely controlled heart failure present significant problems during labour and birth
- > Labour and birth should occur in a hospital with an adult intensive care or cardiac unit

Timing of labour and birth

- > Increased risk of preterm labour
- > Before 30 weeks gestation, in partnership with the woman, the high risk management team (obstetrician, physician, cardiologist and anaesthetist) should discuss and agree on the time and mode of birth
- > Document plan in case notes
- > The time and mode of the birth is ultimately the obstetrician's decision
- > Aim to birth at term if cardiac state is well stabilised
- > Inform the woman of possible management change at short notice if cardiac function and reserve alter rapidly

During labour

- > Contact the cardiologist or physician, anaesthetist and paediatrician before birth
- > Consider [Endocarditis antibiotic prophylaxis](#)
- > Cardiac drugs during labour should be planned in consultation with microbiologist, obstetrician and cardiologist / physician

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Birth

- > To shorten second stage and avoid excessive maternal expulsive efforts:
 - > Consider episiotomy
 - > Consider forceps delivery
 - > Do not use local anaesthetic with adrenaline
- > To minimise cardiac compromise
 - > Do not use stirrups without discussion between obstetrician, anaesthetist and cardiologist / physician
 - > Report a pulse rate > 130 or < 40 bpm
 - > Report respiratory rate > 24 or < 5 rpm
 - > Report rapidly changing pulse or respiration rate (even if within threshold)

Postpartum

Management of the third stage, including complications

- > Many of these women are intolerant of changes in vascular resistance and venous return. Therefore care is required to avoid vasodilatation from bolus doses of Syntocinon®, whilst avoiding excessive bleeding from uterine atony

Oxytocic for active management of the third stage

- > Syntocinon® 10 IU diluted to 9 mL with sodium chloride 0.9 % in a 10 mL syringe
- > Give 2 x 1 mL aliquots (i.e. Syntocinon® 1 IU) 30 seconds apart to produce uterine contraction following delivery of the anterior shoulder
- > Await classic signs of separation of the placenta before attempting to deliver placenta
- > if no signs of separation after 60 seconds give a third aliquot of 1 IU (1mL) of Syntocinon®

Syntocinon Infusion for prevention or control of PPH

- > Syntocinon® 40 IU diluted in 100 mL bag of sodium chloride 0.9 % and run at 25 mL / hour
- > The Syntocinon® is delivered at the normal dose but in 1/10th the volume

Management of PPH

- > Prompt treatment important to avoid hypovolaemia and reduced preload
- > Large boluses of Syntocinon® are contraindicated.
- > Ergometrine and Prostaglandin F2 alpha are contra indicated
- > Rub up a contraction manually and administer 1 mL of dilute Syntocinon® solution (10 IU in 10 mL)
- > Administer misoprostol (Cytotec®) 200 micrograms orally (1 tablet) and 800 micrograms rectally (4 tablets)
- > Judicious resuscitation with assistance of intensive care unit and anaesthetic colleagues

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Observations

- > Observe woman very closely for 24 hours postpartum. This is a high risk period for the woman since blood volume increases from auto transfusion and after load increases as placental bed circulation ceases (Davies, Herbert 2007)
- > Refer and report any signs of cardiac failure:
 - > Dyspnoea
 - > Cyanosis / pallor
 - > Tachycardia
 - > Cold clammy extremities
 - > Haemoptysis
 - > Oedema of the face and hands
- > Take and record the woman's respiration when pulse is taken
- > Continue to position the woman in a semi-upright position
- > Encourage deep breathing and passive leg exercises
- > The clinician should realise that maternal mortality associated with pulmonary hypertension and Eisenmenger syndrome may occur up to several weeks postpartum

Contraception

- > Sterilization of the male partner carries the least risk in monogamous couples who have completed their family
- > Oral contraceptives can be used with several exceptions:
 - > Women with right to left shunts
 - > Cardiac disease with associated hypertension
- > Progestin-only oral contraceptives or medroxy-progesterone acetate (Depo-Provera®) may be used by these women, as the thromboembolic risk of oral contraceptives is thought to be due to the oestrogen component.
- > The progestin-releasing intrauterine contraceptive device (IUCD) has a failure rate of < 1 % and in a monogamous couple the risk of endocarditis associated with the use of an IUCD is rare. Prophylaxis with oral amoxicillin (2 g taken one hour before insertion or removal) is recommended

Follow up

- > Postnatal follow up should be at a high risk medical clinic and with the woman's cardiologist

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Summary

Antenatal Care

Low risk

- > Tertiary hospital
- > Consultation with anaesthetists, cardiologist / obstetric physician in high risk clinic

Intermediate or high risk

- > High risk obstetric centre with multidisciplinary care from obstetrician, anaesthetist, intensivist, neonatologist, midwifery and nursing

Antepartum Management

- > Multidisciplinary approach
- > Serial cardiac assessments to identify and act upon cardiac deterioration
- > Fetal echo for mothers with congenital heart disease +/- genetic counselling
- > Optimise medication for pregnancy
- > Early admission for high risk women

Peripartum Management

Low and intermediate risk

- > Epidural anaesthesia
- > Cardiac telemetry and oximetry if required
- > Deep venous thrombosis (DVT) prophylaxis

High Risk

- > Multidisciplinary approach including decision on delivery in an intensive care unit (ICU) or not and level of invasive monitoring
- > Planned delivery at term
- > Aim for vaginal delivery except in specific instances (e.g. Marfan's, critical aortic stenosis)
- > Care in labour and delivery unit, coronary or intensive care unit if indicated. Continued careful observation using special observation charts and possibly including systems such as 'Early warning scores' for signs of clinical deterioration in the 4th stage

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

FDA classification

Category B:

Either animal reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women, or animal reproduction studies that have shown an adverse effect that was not confirmed in controlled studies in women.

Category C:

Either studies in animals have revealed adverse effects on the fetus and there are not controlled studies in women, or studies in women and animals are not available. Drugs should be given only if potential benefits justify risk to the fetus.

Category D:

There is positive evidence of human fetus risk, but the benefits from use in the pregnant woman may be acceptable despite the risk.

Category X:

Studies in animals or human beings have demonstrated fetal abnormalities. The risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are pregnant.

Source: Drug Information for health care Professionals (USDPI Vol 1); Micromedex; 23rd ed (1 January 2003). Adapted from Elkayam U. Pregnancy and cardiovascular disease. In: Zipes DP, Libby P, Bonow RO, Braunwald E. editors. Braunwald's heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, PA: Elsevier, 2005: 1965 (763).

Adapted from Bonow RO, Carabello BA, Catterjee K, de Leon AC Jr., Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Valvular Heart Disease).

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

References

1. Alfredo F, Gei MD, Hankins GDV. Cardiac disease and pregnancy. *Obstet Gynecol Clinics of North America* 2001; 28: 465 – 512.
2. Liebelt J, Hotham NJ. Birth defects, prenatal diagnosis and teratogens. In: Robinson MJ, Robertson DM, editors. *Practical paediatrics*. 5th ed. New York: Churchill Livingstone; 2002. p. 270.
3. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. *Circulation* 2001; 104: 515-521.
4. Gei AF, Hankins GDV. Cardiac disease and pregnancy. *Obstet Gynecol Clin North America* 2001; 28: 465 – 513.
5. Davies GAL, Herbert WNP. Heart disease in pregnancy 1. Assessment and management of cardiac disease in pregnancy. *JOGC* 2007a; 29: 331-336.
6. Davies GAL, Herbert WNP. Heart disease in pregnancy 2. Congenital heart disease in pregnancy. *JOGC* 2007b; 29: 409-414.
7. Davies GAL, Herbert WNP. Heart disease in pregnancy 3. Acquired heart disease in pregnancy. *JOGC* 2007c; 29: 507-509.
8. Davies GAL, Herbert WNP. Heart disease in pregnancy 4. Ischemic heart disease and cardiomyopathy in pregnancy. *JOGC* 2007d; 29: 575-579.
9. Davies GAL, Herbert WNP. Heart disease in pregnancy 5. Prosthetic heart valves and arrhythmias in pregnancy. *JOGC* 2007e; 29: 635-639.
10. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Valvular Heart Disease). American College of Cardiology Web Site. Available at: <http://www.acc.org/clinical/guidelines/valvular/index.pdf>.
11. American Heart Association (AHA). Prevention of infective endocarditis: Guidelines from the AHA. *Circulation* 2007; 116: 1736-54
12. Klein LL, Galan HL. Cardiac disease in pregnancy. *Obstet Gynecol Clin* 2004; 31: 1 – 24.
13. Dobbenga-Rhodes YA, Privé AM. Assessment and evaluation of the woman with cardiac disease during pregnancy. *J Perinat Neonat Nurs* 2006; 20: 295-302.
14. Chia P, Chia H, Subramaniam R. A clinical approach to heart disease in pregnancy. Part 2: specific considerations in management. *The Obstetrician and Gynaecologist* 2002; 4: 212 – 6.
15. Blanchard DG, Shabetai R. Cardiac diseases. In: Creasy RK, Resnik R, Iams JD editors. *Maternal fetal medicine. Principles and practice*. 5th ed. Philadelphia: Saunders; 2004. p. 815 – 843.
16. Tomlinson MW, Cotton DB. Cardiac disease. In: James DK, Steer PJ, Weiner CP, Gonik B editors. *High risk pregnancy: management options*. 2nd ed. London: Harcourt; 1999. p. 685 – 707.
17. Witcher PM, Harvey CJ. Modifying labor routines for the woman with cardiac disease. *J Perinat Neonat Nurs* 2006; 20: 303-310.
18. Davies GAL, Herbert WNP. Heart disease in pregnancy 1. Assessment and management of cardiac disease in pregnancy. *JOGC* 2007; 29: 331-336.
19. Subramaniam P, Robson S. Heart transplant and pregnancy. *Obstetrics and Gynaecology* 2008; 10: 32-35.

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Abbreviations

NYHA	New York Heart Association
e.g.	For example
EDC	Estimated date of confinement
ECG	Electrocardiogram
AFI	Amniotic fluid index
TOP	Termination of pregnancy
SVT	Supraventricular tachycardia
AV	Atrio ventricular
RF	Radio frequency
ICD	Internal cardiac defibrillator
PA	Pulmonary artery
DC	Direct current
BSA	Body surface area
ACE	Angiotensin converting enzyme
TCPC	Total cavopulmonary connection
MI	Myocardial infarction
CEMCH	Confidential Enquiry into Maternal and Child Health
AHA	American Heart Association
UFH	Unfractionated heparin
LMWH	Low molecular weight heparin
INR	International normalised ratio
APTT	Activated Partial Thromboplastin Time
mL	Millilitre(s)
mg	Milligram(s)
AS	Atrial stenosis
AR	Atrial regurgitation
MS	Mitral stenosis
MR	Mitral regurgitation
BPM	Beats per minute
LV	Left ventricular
EF	Ejection fraction
RPM	Respirations per minute
IU	International unit(s)
ICU	Intensive care unit
IUCD	Intrauterine contraceptive device
g	Gram(s)
DVT	Deep venous thrombosis
ACC	American College of Cardiology
CCU	Coronary care unit

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Table 64.1 Allocation of care according to severity of cardiac disease

Cardiac condition	Tertiary centre	Tertiary centre
Primary pulmonary hypertension		Yes
Eisenmenger syndrome		Yes
Uncorrected coarctation of the aorta		Yes
AS	Mild to moderate stenosis	Severe with or without symptoms Ao valve area < 1.0 cm ²
AR	NYHA functional Class I-II	NYHA functional III-IV
MS	NYHA functional Class I	NYHA functional class II-IV Valve area < 1.5 cm ² PA systolic pressure > 50 mm Hg or > 75 % systemic pressure
MR	Yes NYHA functional Class I-II	Yes NYHA functional class III-IV
Aortic and / or mitral valve disease resulting in severe pulmonary hypertension		Yes (pulmonary pressure > 75 % of systemic pressures)
Aortic and / or mitral valve disease with severe LV dysfunction		Yes (EF < 0.40)
Mechanical prosthetic valve requiring anticoagulation		Yes
Marfan syndrome		Yes with aortic complications, with or without AR
History of peripartum cardiomyopathy		Yes with persistent left ventricular dysfunctions and NYHA functional Class IV
Pacemakers	Yes	
Implanted Cardioverter Defibrillator management in pregnancy		Yes
Management of ventricular arrhythmias		Yes

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Table 64.2 Maternal mortality CEMACH 2003-2005

Type and cause of death	Indirect	Late
Acquired		
Aortic Dissection	9	0
Myocardial Infarction	12	4
Ischaemic Heart disease		0
Sudden Adult Death Syndrome	4	9
Peripartum Cardiomyopathy	3	12
Cardiomyopathy	0	4
Myocarditis or myocardial fibrosis	1	0
Mitral valve disease	5	0
Infectious endocarditis	3	2
Right or left ventricular hypertrophy or hypertensive heart failure	2	1
Congenital		
Pulmonary hypertension	3	0
Congenital heart disease	3	2
Total	47	34

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Table 64.3 CEMACH 2003-2005 Indirect maternal deaths

Triennium	Congenital	Acquired		Total	Rate	95 per cent CI	
		Ischaemic	Other				
	n (%)	n (%)	n (%)	n (%)			
1985-1987	10 (43)	9 (39)	4 (17)	23 (100)	1.01	0.68	1.52
1988-1990	9 (50)	5 (28)		18 (100)	0.76	0.48	1.21
1991-1993	9 (24)	8 (22)		37 (100)	1.60	1.16	2.20
1994-1996	10 (26)	6 (15)		39 (100)	1.77	1.30	2.43
1997-1999	10 (29)	5 (14)		35 (100)	1.65	1.19	2.29
2000- 2002	9 (20)	8 (18)		44 (100)	2.20	1.64	2.69
2003- 2005	4 (8)	16 (33)		48 (100)	2.27	1.67	2.96

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Table 64.4 Cardiovascular Drugs in Pregnancy

Drug	Use in pregnancy	Potential side effects	Breast feeding	Risk factors
Adenosine	Maternal and fetal arrhythmias	No side effects reported; data on use during first trimester are limited	Data NA	C
Amiodarone	Maternal arrhythmias	IUGR; prematurity, congenital goitre, hypothyroidism and hyperthyroidism, transient bradycardia, and prolonged QT in the newborn	Not recommended	C
Angiotensin-converting enzyme inhibitors / Angiotensin receptor II antagonist	Hypertension; heart failure	Oligohydramnios, IUGR, prematurity, neonatal hypotension, renal failure, anaemia, death, skull ossification defect, limb contractures, patent ductus arteriosus	Compatible	D
Beta blockers	Hypertension, maternal arrhythmias, myocardial ischemia, mitral stenosis, hypertrophic cardiomyopathy, hyperthyroidism, Marfan syndrome	Fetal bradycardia, low placental weight, IUGR, hypoglycaemic, no information on carvedilol	Compatible, monitoring of infant's heart rate recommended	Acebutolol: B Labetalol: C Metoprolol: C Propranolol: C Esmolol: C Atenolol: D
Digoxin	Maternal and fetal arrhythmias, heart failure		Compatible	C
Diltiazem	Myocardial ischemia, tocolysis		Compatible	C
Diuretics	Hypertension, congestive heart failure	Hypervolemia leads to reduced uteroplacental perfusion, fetal hypoglycaemia, thrombocytopenia, hypernatremia, hypokalaemia, thiazide diuretics can inhibit labour and suppress lactation	Compatible	C

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Drug	Use in pregnancy	Potential side effects	Breast feeding	Risk factors
Flecainide	Maternal and fetal arrhythmias	Limited data; 2 cases of fetal death after successful treatment of fetal SVT reported, but relation to flecainide uncertain	Compatible	C
Heparin	Anticoagulation	None reported	Compatible	C
Hydralazine	Hypertension	None reported	Compatible	C
Lignocaine	Local anaesthesia, maternal arrhythmias	No evidence for unfavourable fetal effects; high serum levels may cause central nervous depression at birth	Compatible	C
Nifedipine	Hypertension, tocolysis	Fetal; distress related to maternal hypotension reported	Compatible	C
Nitrates	Myocardial infarction and ischemia, hypertension, pulmonary oedema, tocolysis	Limited data; use is generally safe, few cases of fetal heart rate deceleration and bradycardia have been reported	Data NA	C
Procainamide	Maternal and fetal arrhythmias	Limited data; no fetal side effects reported	Compatible	C
Sodium nitroprusside	Hypertension, aortic dissection	Limited data; potential thiocyanate fetal toxicity, fetal mortality reported in animals	Data NA	C
Sotalol	Maternal arrhythmias, hypertension, fetal tachycardia	Limited data, 2 cases of fetal death and 2 cases of significant neurological morbidity in newborns reported, as well as bradycardia in newborns	Compatible, monitoring of infant's heart rate recommended	B
Verapamil	Maternal and fetal arrhythmias, hypertension, tocolysis	Limited data; other than a single cases	Compatible	C
Warfarin	Anticoagulation	Crosses placental barrier; fetal haemorrhage in utero, embryopathy, central nervous system abnormalities	Compatible	X

IUGR indicates intrauterine growth restriction, NA – not available; SVT – supraventricular tachycardia

Cardiac Disease in Pregnancy

© Department of Health, Government of South Australia. All rights reserved.

Version control and change history

PDS reference: OCE use only

Version	Date from	Date to	Amendment
1.0	06 April 10	current	Original version